Authors: Debrix, I Tilleul, P Milleron, B Grene, N Bouleuc, C Roux, D Liote, H Madelaine, I Bellanger, A Conort, O Fontan, JE Le Mercier, F Bardin, C Becker, A

Citation: I. Debrix et al., The relationship between introduction of American Society of Clinical Oncology guidelines and the use of colony-stimulating factors in clinical practice in a Paris university hospital, CLIN THER, 23(7), 2001, pp. 1116-1127

Authors: Faivre, L Saoudi, S Astier, A Hamadas, C Conort, O Boivin, H Sabatier, B Taburet, AM Lecointre, K Bellanger, A Radideau, E Thuillier, A

Citation: L. Faivre et al., FK 506 dose in transplantation: From theory to practice, TRANSPLAN P, 33(4), 2001, pp. 2594-2597

Authors: Levy-Piedbois, C Durand-Zaleski, I Juhel, H Schmitt, C Bellanger, A Piedbois, P

Citation: C. Levy-piedbois et al., Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer, ANN ONCOL, 11(2), 2000, pp. 157-161

Authors: Fagot, JP Flahault, A Kanfer, A Benoit, G Bellanger, A Conort, O Durand-Zaleski, I Liote, H Mangin, L Oliary, J Verdy, E Becker, A

Citation: Jp. Fagot et al., Prevention of venous thromboembolism in patients hospitalized for more than 24 hours in a medical ward: proposed indications for low molecular weightheparins, PRESSE MED, 29(1), 2000, pp. 4-10

Authors: Montalescot, G Polle, V Collet, JP Leprince, P Bellanger, A Gandjbakhch, I Thomas, D

Citation: G. Montalescot et al., Low molecular weight heparin after mechanical heart valve replacement, CIRCULATION, 101(10), 2000, pp. 1083-1086